Announced details
New drugs that control protein-protein interactions (PPIs), and the cancer and fibrosis fields
The Company had its patent application examined in the United States for an invention it filed.
Application No. 18/014,556. A notice of allowance has been issued, and the application will become a registered patent after payment of the patent fee. Validity period: Not disclosed
No impact on the Company's financial results for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PepMetics® technology library compound series / PepMetics® technology |
| Counterparty | United States Patent and Trademark Office (the institution is not named in the body) |
| Relationship with the Company | The Company had its patent application examined in the United States for an invention it filed. |
| Applicable area | New drugs that control protein-protein interactions (PPIs), and the cancer and fibrosis fields |
| Registration number and expiry date | Application No. 18/014,556. A notice of allowance has been issued, and the application will become a registered patent after payment of the patent fee. Validity period: Not disclosed |
| Impact on Business Performance | No impact on the Company's financial results for the fiscal year ending December 2026 |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Securing rights in the United States is expected to enhance the exclusivity of the Company's compound space and contribute to improving corporate value over the medium to long term.